Indianapolis, Indiana, September 15, 2026
Eli Lilly and Company will present new clinical and scientific data for Foundayo (orforglipron), retatrutide and eloraTZP at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting, highlighting the company’s expanding portfolio of medicines targeting diabetes, obesity and broader cardiometabolic health. The presentations will include new findings from clinical development programs evaluating the effects of Lilly’s investigational and recently developed therapies on blood glucose, body weight and cardiometabolic risk factors. The data package is expected to provide additional insights into how incretin-based and next-generation metabolic therapies could influence the treatment landscape for people living with obesity and diabetes. Lilly said the breadth of its EASD 2026 program reflects its goal of developing medicines that can potentially change the course of cardiometabolic disease.
Lilly Highlights Foundayo and Retatrutide Data
A major focus of Lilly’s EASD 2026 presentations will be Foundayo (orforglipron), an oral small-molecule GLP-1 receptor agonist being developed for chronic weight management and other metabolic indications. As an oral therapy, Foundayo could provide an alternative to injectable approaches for eligible patients and potentially broaden access to GLP-1-based treatment. Lilly will also present new data on retatrutide, the company’s investigational once-weekly injectable medicine that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon. The multi-receptor mechanism is being studied for its potential to produce substantial reductions in body weight while also improving metabolic health. Retatrutide remains an investigational medicine, and its safety and effectiveness have not yet been established for any indication. The company’s EASD program is expected to provide further evidence from ongoing clinical studies, helping researchers understand the potential benefits and characteristics of these therapies across different patient populations. Additional clinical data can also help inform future development strategies and regulatory submissions.
EloraTZP Expands Lilly’s Metabolic Pipeline
Lilly will additionally present data related to eloraTZP, another investigational therapy within its expanding cardiometabolic development portfolio. The program reflects the company’s continued investment in medicines designed to address the interconnected conditions of obesity, type 2 diabetes and cardiovascular risk. Cardiometabolic diseases represent a major global health burden because excess body weight, insulin resistance, diabetes, hypertension and cardiovascular disease frequently occur together. New therapies that can address several of these risk factors simultaneously could have an important impact on long-term health outcomes. By presenting data across multiple programs at EASD 2026, Lilly aims to demonstrate the breadth of its research into metabolic disease and the potential of different therapeutic approaches. The company’s development strategy includes both oral and injectable medicines, potentially giving physicians and patients more choices as the treatment landscape evolves.
Advertisement
New Evidence Targets Cardiometabolic Health
The growing availability of highly effective metabolic medicines is changing how researchers approach obesity and diabetes treatment. Rather than focusing solely on short-term glucose or weight reduction, current research increasingly examines whether metabolic therapies can influence broader health outcomes and reduce the long-term consequences associated with cardiometabolic disease. Lilly’s EASD presentations will contribute to this evolving scientific discussion by providing new clinical evidence across its portfolio. For researchers and healthcare professionals, the data may offer additional insight into treatment response, tolerability and the potential role of emerging therapies in different stages of metabolic disease. The company is pursuing clinical development programs designed to establish the safety and efficacy of its investigational medicines. Regulatory decisions will ultimately depend on the totality of clinical evidence generated through these studies. The EASD 2026 meeting therefore represents an important scientific platform for Lilly to share updates from its cardiometabolic research pipeline. New findings for Foundayo, retatrutide and eloraTZP could help clarify the future potential of these medicines and their role in addressing major metabolic health challenges. For cGxP.wire readers, the announcement provides a significant update on pharmaceutical innovation in diabetes, obesity and cardiometabolic medicine. The combination of established and investigational programs demonstrates the industry’s continued focus on developing therapies capable of addressing multiple dimensions of metabolic health. As additional clinical data emerge, Lilly’s programs will remain important developments to watch in the rapidly evolving field of cardiometabolic drug development.
Source: Eli Lilly press release
